Scarica l'app Stockscreener
2.69
1.10%
-0.03
Precedente Chiudi:
$2.72
Aprire:
$2.77
Volume 24 ore:
98,046
Relative Volume:
0.33
Capitalizzazione di mercato:
$72.82M
Reddito:
-
Utile/perdita netta:
$-49.81M
Rapporto P/E:
-1.2477
EPS:
-2.156
Flusso di cassa netto:
$-42.93M
1 W Prestazione:
-8.19%
1M Prestazione:
+10.25%
6M Prestazione:
-39.00%
1 anno Prestazione:
-78.57%
Intervallo 1D:
$2.66
$2.79
Intervallo di 1 settimana:
$2.66
$3.08
Portata 52W:
$1.60
$17.55
Alto Neuroscience Inc Stock (ANRO) Company Profile
Nome
Alto Neuroscience Inc
Settore
Industria
Telefono
773-255-5012
Indirizzo
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Confronta ANRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
2.69 | 79.32M | 0 | -49.81M | -42.93M | -2.156 |
|
ONC
Beone Medicines Ltd Adr
|
246.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.09 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
77.49 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-23 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| 2024-10-23 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-09-03 | Iniziato | Wedbush | Outperform |
| 2024-02-27 | Iniziato | Jefferies | Buy |
| 2024-02-27 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-27 | Iniziato | Stifel | Buy |
| 2024-02-27 | Iniziato | TD Cowen | Outperform |
| 2024-02-27 | Iniziato | William Blair | Outperform |
Mostra tutto
Alto Neuroscience Inc Borsa (ANRO) Ultime notizie
Alto Neuroscience, Inc. Presents Data At the 2025 American Society of Clinical Psychopharmacology Annual Meeting - marketscreener.com
Alto Neuroscience reports progress in depression drug trials - Investing.com Australia
Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder - Yahoo Finance
Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
Northern Trust Corp Acquires 390,190 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
HC Wainwright Issues Pessimistic Outlook for ANRO Earnings - Defense World
Q2 Earnings Forecast for Alto Neuroscience Issued By Wedbush - Defense World
Alto Neuroscience, Inc.: Promising Clinical Trials and Strong Financial Position Justify Buy Rating - TipRanks
Equities Analysts Set Expectations for ANRO Q1 Earnings - Defense World
Wedbush Reiterates Neutral Rating for Alto Neuroscience (NYSE:ANRO) - Defense World
Alto Neuroscience Advances Precision Psychiatry Pipeline - TipRanks
Alto Neuroscience Reports First Quarter 2025 Financial Results And Recent Business Highlights - marketscreener.com
Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Acquired by Barclays PLC - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $15.40 Average Target Price from Brokerages - Defense World
Stifel Financial Corp Takes $544,000 Position in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience (ANRO) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Trading Day Triumph: Alto Neuroscience Inc (ANRO) Ends at 2.17, a -0.91 Surge/Plunge - DWinneX
JPMorgan Chase & Co. Trims Stock Holdings in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience presents new data at Society of Biological Psychiatry meeting - TipRanks
Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach - Business Wire
Press Release Distribution & PR Platform - ACCESS Newswire
Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day - Business Wire
Analysts Set Alto Neuroscience, Inc. (NYSE:ANRO) PT at $15.40 - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Wellington Management Group LLP Has $326,000 Stake in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Analysts Set Expectations for ANRO Q1 Earnings - Defense World
Alto Neuroscience initiated with a Buy at H.C. Wainwright - Yahoo Finance
Alto Neuroscience (NYSE:ANRO) Now Covered by Analysts at HC Wainwright - Defense World
HC Wainwright & Co. Initiates Coverage of Alto Neuroscience (ANRO) with Buy Recommendation - Nasdaq
Charles Schwab Investment Management Inc. Sells 32,137 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Acquired by Bank of New York Mellon Corp - Defense World
ANRO stock touches 52-week low at $2.33 amid market challenges - Investing.com Australia
What is William Blair’s Forecast for ANRO Q1 Earnings? - Defense World
What is Wedbush’s Estimate for ANRO FY2029 Earnings? - Defense World
Brokerages Set Alto Neuroscience, Inc. (NYSE:ANRO) PT at $16.75 - Defense World
William Blair Reiterates “Outperform” Rating for Alto Neuroscience (NYSE:ANRO) - Defense World
Alto Neuroscience says its funded through 2028 - Green Market Report
ALTO NEUROSCIENCE Earnings Results: $ANRO Reports Quarterly Earnings - Nasdaq
Alto Neuroscience Inc. (ANRO) reports earnings - Quartz
Alto Neuroscience Reports Full-Year 2024 Financial Results And Recent Business Highlights - Marketscreener.com
Alto Neuroscience, Inc. SEC 10-K Report - TradingView
Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights - Business Wire
Alto Neuroscience (ANRO) Expected to Announce Quarterly Earnings on Thursday - Defense World
ANRO stock touches 52-week low at $3.23 amid market challenges - MSN
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Bought by Rhumbline Advisers - Defense World
Schizophrenia Drugs Market: Top Competitors, Market Share, - openPR
Alto Neuroscience (NYSE:ANRO) Trading Up 8.8% – Should You Buy? - Defense World
Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock - Asianet Newsable
1 ‘Strong Buy’ Penny Stock With 270% Upside to Load Up On in March - MSN
1 ‘Strong Buy’ Penny Stock With 270% Upside To Load Up On In March - Barchart
Alto Neuroscience Inc Azioni (ANRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):